🔓 Unlock the full profile of Natalie Kelley (Day One Biopharmaceuticals), including verified contact details, financial insights, and professional associations.
See Natalie Kelley Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: nat*****@day******.com
Mobile: 76197*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Natalie Kelley serves as the Founder of Day One Biopharmaceuticals, a role that emphasizes leadership in developing innovative treatments for pediatric cancer.
- Under Natalie's leadership, Day One Biopharmaceuticals has grown significantly since its founding in 2018, achieving a market capitalization of approximately $685.2 million.
- The organization is publicly traded on NASDAQ under the symbol DAWN, reflecting its establishment as a key player in biopharmaceuticals.
- Day One Biopharmaceuticals has focused on addressing unmet medical needs for children with cancer, positioning itself uniquely within the biopharmaceutical market.
- Natalie also operates as a Biotech Business Operations Consultant and Leadership Coach through Kelley Consulting LLC, which began in 2023, indicating a commitment to nurturing talent within the industry.
- In addition, Natalie founded ForecastLite, a consulting venture that began in 2023, which specializes in operational forecasting for biopharmaceutical companies.
- Prior to these endeavors, Natalie held senior roles at Global Blood Therapeutics, where they served as Senior Director of Business Operations and Analytics, contributing to the operational efficiencies of the organization.
- Natalie's extensive experience includes roles such as Business Consultant for Process Design at Future State and a Clinical Research Associate, showcasing a broad spectrum of expertise in the biopharmaceutical field.
- Educational background and previous positions in clinical research and consultancy provide a solid foundation for strategic decision-making and operational excellence at Day One Biopharmaceuticals.